CAR T-Cell Therapy Market size was valued at USD 5.9 billion in 2024 and is likely to cross USD 140.25 billion by 2037, registering more than 27.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of CAR T-cell therapy is estimated at USD 7.28 billion.
CAR T-Cell Therapy Market size was over USD 4.62 billion in 2023 and is anticipated to cross USD 109.82 billion by 2036, growing at more than 27.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of CAR T-cell therapy is estimated at USD 5.64 billion.
Growth Drivers
Rising Cases of Cancer Globally to Drive the Market Growth
According to the Leukemia & Lymphoma Society, approximately one person in the United States is diagnosed with a form of blood cancer every 3 minutes. Moreover, it was estimated that a total of 176,200 people in the U.S. would be diagnosed with leukemia, myeloma or lymphoma in 2019. Further, leukemia, myeloma and lymphoma were predicted to account for 10% of the total new cancer cases in 2019. The growing cases of various types of cancer all across the globe are estimated to become the major factor responsible for the growth of CAR T cell therapy market. As a result of this, the demand for effective treatment methods for cancer, which are targeted, increases significantly.
Growing Demand for CAR T Cell Therapy as Opposed to Alternate Therapies to Boost the Market Growth
In 2017, the U.S. FDA approved Kymriah, a CAR T cell therapy for the treatment of large B cell lymphoma in adult patients. The therapy, developed by Novartis, can further be used for the treatment of adult patients with acute lymphoblastic leukemia, diffuse large B cell lymphoma (DLBCL) and DLBCL arising due to follicular lymphoma. The property of CAR T cell therapies to be used for various types of cancer and treat multiple forms of lymphoma is a major growth factor for the market.
Challenges
Side Effects Associated with CAR T-Cell Therapy to Hamper the Market Growth
The various side effects associated with the CAR T cell therapy, such as cytokine release syndrome (CRS), pyrexia, reduced appetite, hypotension, headache, encephalopathy, nausea, bleeding and edema among several others are estimated to restrict the CAR T-cell therapy market growth. In addition to the harmful side effects, the high cost of obtaining this therapy is predicted to be another important factor hampering the market growth over the forecast period.
The CAR T-cell therapy market is segmented by indication, by target antigen and by region. On the basis of indication, the market is further segmented into acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL) and others, out of which, the DLBCL segment is anticipated to hold the largest share in the market on account of growing cases of the condition which raise the demand for CAR T-cell therapy. The segment for multiple myeloma is another segment anticipated to observe significant growth in the market as a result of rising research and development in that area. Based on target antigen, the market is segmented into CD19, CD20, CD22, CD30, GD2 and others. Out of these, the segments for CD19 and CD20 target antigens are anticipated to hold the largest shares in the CAR T-cell therapy market. This can be attributed to the high approval rate of therapies containing these antigens.
Our in-depth analysis of the global market includes the following segments:
|
By Indication |
|
|
By Target Antigen |
|
On the basis of regional analysis, the CAR T-cell therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The market for CAR T cell therapy is predicted to hold the leading share in the North America industry is predicted to account for largest revenue share by 2037, attributed to growing research and developments taking place in the field of CAR T cell therapy and cancer treatments in the region along with increasing number of treatments receiving approval by the U.S. Food and Drug Administration (FDA).are estimated to further boost the market growth. For instance, Kymriah is a CAR T cell therapy manufactured by Novartis and approved by the FDA in 2017. The therapy is for the treatment of acute lymphoblastic leukemia. The market in Europe is anticipated to hold the second largest share in the market as a result of growing approvals of CAR T cell therapies such as Kymriah and Yescarta by the European Medicines Agencies (EMA), which is further predicted to increase the CAR T-cell therapy market size over the coming years.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?